Introduction
The prevalence of polycystic ovary syndrome (PCOS) in the general female population ranges from 5-10%, 1,2 and the disease accounts for nearly 73% of cases of anovulatory infertility. 3, 4 The disease process is characterized by variable degrees of hyperandrogenism, morphologic changes in the ovary, inappropriate gonadotropin secretion, and insulin resistance -all of which contribute to the phenotype of ovulatory dysfunction and infertility. 5 Obesity, defined by the World Health Organization (WHO) as a body mass index (BMI) of >30 kg/m 2 , is an increasing health concern in the United States.
Recent estimates identify greater than 31% of reproductive-aged American women as obese, and nearly 55% as overweight (BMI >25 kg/m 2 ). 6 A majority of PCOS patients are overweight or obese, 1 and obesity contributes to several metabolic alterations that interfere with normal ovulation through increased peripheral aromatization resulting in hyperestrogenemia, decreased sexhormone binding globulin (SHBG) resulting in increased free testosterone levels, and hyperinsulinemia resulting in higher thecal androgen production. 4, 7 Despite its strong association with the disease, obesity is not requisite for the diagnosis of PCOS and approximately 25-30% of women with PCOS are of normal BMI (18.5-25 kg/m 2 ). These women are thought to be at lower risk for the metabolic dysfunction typically associated with PCOS, indicating that obesity, rather than PCOS, may be the primary contributor to this risk. 8 There is little data describing fertility potential in the lean PCOS variant. A few recent studies have compared in vitro fertilization (IVF) outcomes in the lean versus obese PCOS populations, with two groups reporting lower pregnancy rates in obese PCOS patients 9, 10 and a third reporting no difference. 11 Even less is known about the impact of BMI on pregnancy outcome in PCOS patients undergoing ovulation induction (OI), despite this being considered the first line treatment for this population.
We sought to compare clinical pregnancy rates (CPR) between lean, overweight, and obese PCOS patients undergoing ovulation induction and intrauterine insemination (OI-IUI) with oral (oral OI-IUI) or combined oral and injectable medications (combined OI-IUI).
Materials and Methods

Study Population
The study population included women aged 21-43 who underwent OI-IUI at the University of Iowa between January 2000 and November 2013. Analyses were restricted to women with the sole infertility diagnosis of PCOS as defined by the 2003 Rotterdam criteria.
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Couples who had multiple infertility diagnoses (including endometriosis, tubal factor, or diminished ovarian reserve) were excluded, as were those with severe male factor, as defined by a pre-wash total motile sperm count of less than 10 million averaged over all semen analyses performed. Pregnancy outcome data was lacking for three patients during the study period and these individuals were also excluded from analyses. The method of ovulation induction was selected by the individual provider, and consisted of either oral ovulation induction with clomiphene citrate or letrozole, or combined oral/injectable ovulation induction with clomiphene citrate or letrozole in conjunction with gonadotropins. Oral ovulation induction cycles were typically monitored using home urinary luteinizing hormone (LH) kits, whereas combined oral/injectable ovulation induction cycles were monitored with serial sonographic measurements of follicular growth beginning on treatment day 8. Spontaneous ovulation was permitted in oral ovulation induction cycles, whereas 250 mcg of subcutaneous recombinant human chorionic gonadotropin (hCG) was used to trigger ovulation in combined oral/injectable ovulation induction cycles. IUI was performed 36 hours after hCG trigger or 24 hours after a positive home urinary LH kit. The study was approved by the Institutional Review Board at The University of Iowa. . Lean women were used as the referent population for all comparisons.
Exposure and outcome variables
The primary outcome was clinical pregnancy, defined as sonographic evidence of intrauterine gestational sac on ultrasound. Clinical pregnancy rates were calculated per completed IUI.
Potential confounding variables
Female age, parity, and IUI attempt number were documented at cycle start. Other patient variables assessed at the time of IUI included current smoking status (yes/no), current metformin use (yes/no), semen parameters (average pre-wash total motile count averaged for all IUI cycles), and duration of infertility (months). Documented cycle characteristics included type of OI (letrozole, clomiphene citrate, +/-gonadotropins), utilization of an hCG trigger (yes/no), and for combined OI-IUI cycles, total number of follicles and number of follicles > 15mm on day of hCG trigger.
Statistical Analysis
Logistic regression was used to estimate the effect of BMI on clinical pregnancy, adjusting for potential confounders including parity, cycle number, smoking status, metformin use, semen parameters, type of oral agent used, utilization of hCG trigger, and total number of follicles and number of follicles > 15mm on day of hCG trigger for combined OI-IUI cycles. Female age and duration of infertility were included a priori as covariates in the model. Other potential confounders were examined but resulted in a less than 10% change in the effect estimates and were therefore not included in the final model. Generalized estimating equations were used to account for the correlation between multiple cycles in the same patient. Results were expressed as adjusted odds ratios (OR) with 95% confidence intervals (CI), using lean women as the referent population.
Results
One hundred ninety eight women with PCOS contributed a total of 440 cycles to the analysis: 114 cycles from 48 lean women, 87 cycles from 38 overweight women, 146 cycles from 65 obese women, and 93 cycles from 47 morbidly obese women. Demographic characteristics of the study population are listed in Table 1 .
Fifty-seven percent of participants were obese or morbidly obese. Patient age and duration of infertility both rose with increasing BMI, whereas smoking status, parity, and average total motile sperm counts were similarly distributed across all BMI categories. Use of metformin was more common among obese women.
There was more clomiphene use in the oral OI-IUI cycles (66% of all cycles), and more letrozole use (75% of all cycles) in the combined OI-IUI cycles. The total number of follicles measured on ultrasound at time of hCG trigger in combined OI-IUI cycles was higher for lean patients than overweight or obese patients, though the median number of follicles >15mm at time of hCG injection did not substantially differ between BMI categories. Unadjusted rates of clinical pregnancy after the first cycle of oral OI-IUI showed no consistent association with patient BMI, but trended downward when all cycles were examined ( Table 2) .
Adjusted analyses did not reveal a significant difference in odds of clinical pregnancy in overweight and obese women as compared to the lean PCOS referent population (Figure 1 ). In lean PCOS patients undergoing combined OI-IUI, the unadjusted CPR for all cycles was 52%; CPR was comparatively lower in overweight (22%), obese (27%) and morbidly obese (21%) women (Table 2) 
Discussion
The results of this study demonstrate a significant negative association between increasing patient BMI and rates of clinical pregnancy in women with PCOS undergoing combined ovulation induction and intrauterine insemination with oral and injectable medications. Although a similar association was not identified in women with PCOS undergoing ovulation induction and intrauterine insemination with oral agents, analyses were limited by the small number of total pregnancies in this population and the possibility of a difference cannot therefore be excluded.
Retrospective studies have evaluated the effects of BMI on IVF cycle outcomes in women with PCOS, 9-11 with discrepant results.
A recent study demonstrated a 66% lower odds of clinical pregnancy in obese (BMI>30 kg/m 2 ) as compared to lean (BMI<25 kg/m 2 ) women with PCOS after adjusting for female age, gravidity, day 3 follicle stimulating hormone (FSH), and male factor infertility. 10 A similar increase in clinical pregnancy rates in lean women with PCOS as compared to those with BMI>25 kg/m 2 was identified by a second study that also demonstrated a preferential benefit of GnRH-agonist stimulation protocols in the lean cohort. 9 A third study comparing lean and obese women without PCOS to lean and obese women with PCOS demonstrated a greater number of retrieved oocytes in lean as compared to obese women with PCOS, but noted comparable rates of clinical pregnancy and live birth in all groups. The results of this study were significantly limited by its small sample size which included only six lean patients with PCOS. 11 These studies suggest that lean PCOS patients may have a differential response to ovarian stimulation in the setting of IVF, but could not comment on the association with more conservative types of infertility treatment. A single retrospective study of 270 women directly investigated the impact of obesity on cycle outcome in women with PCOS undergoing ovulation induction. Treatment was initiated with clomiphene, and if no ovulation was documented in three cycles despite dose escalation, extended to gonadotropins. Women who ovulated successfully with clomiphene were given up to six cycles to conceive before gonadotropin therapy.
The authors identified lower rates of ovulation and clinical pregnancy with increasing BMI, but data were unadjusted and did not account for key confounding factors including patient age. 4 The study demographics also indicated a mean BMI of 28.5 +/-5.5 kg/m 2 , which may limit the generalizability of its results to populations with a higher prevalence of obesity.
Some key limitations should be considered when interpreting our results.
The study population was identified retrospectively from our institution's database of couples undergoing IUI. Pregnancy rates could accordingly only be determined per IUI, not per cycle start. Cycles that were cancelled prior to IUI were therefore not included in the database, which may falsely elevate the overall rates of clinical pregnancy.
This may have particular relevance in lean women with PCOS undergoing combined OI-IUI, a population with a significant risk of cycle cancellation due to multi-follicular development, where our unadjusted pregnancy rates were as high as 50-60%. A false elevation in CPR among lean women could overestimate the potential negative impact of obesity on odds of clinical pregnancy in the PCOS population, thus skewing our results away from the null hypothesis. This is supported by the absence of an association in the oral ovulation induction group where cycle cancellation rates are likely to be low. It can be argued, however, that morbidly obese women may also have a high risk of cycle cancellation due to provider desire to avoid multiple gestation pregnancies due to the significant obstetric consequences in this population. If this risk outweighs that of lean women, this may underestimate the impact of obesity on cycle outcome and skew data towards the null. It is worth noting, however, that adjusting for the total number of follicles and number of follicles >15mm on the day of hCG trigger did not substantially change the effect estimates, suggesting that the negative impact of obesity on odds of clinical pregnancy may be independent of differences in ovarian response to OI. Additional limitations include the nonstandardized selection of patients for either oral or combined OI-IUI as well as the lack of statistical power to examine other outcomes of interest such as miscarriage or multiple pregnancy.
Despite these limitations, this study is unique in its ability to examine the association between a wide range of patient BMI and outcome of ovulation induction in a well-defined cohort of PCOS patients. The large number of total IUI cycles afforded us the ability to account for variables including age and duration of infertility that may confound the relationship between BMI and cycle outcome, particularly in the combined OI-IUI cycles.
Future prospective validation of these findings would afford the ability to examine differences in the medication dose required to achieve ovulation and account for the impact of cycle cancellation.
Given the limited existing literature on response to ovulation induction in these populations, this study provides useful data for patient counseling with respect to infertility treatment selection. The results of this study suggest that lean women with PCOS have higher pregnancy rates after combined OI-IUI with oral and injectable agents as compared to their overweight, obese, and morbidly obese counterparts, and may preferentially benefit from this treatment approach.
